Shares of Johnson & Johnson (NYSE:JNJ) have earned a consensus recommendation of “Buy” from the seventeen brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $142.80.
A number of brokerages have recently issued reports on JNJ. Zacks Investment Research reaffirmed a “sell” rating on shares of Johnson & Johnson in a research note on Monday, December 31st. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 2nd. Barclays reaffirmed an “equal weight” rating and issued a $135.00 price objective (down previously from $137.00) on shares of Johnson & Johnson in a research note on Wednesday, January 23rd. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $152.00 price objective (down previously from $162.00) on shares of Johnson & Johnson in a research note on Monday, January 14th. Finally, ValuEngine raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Thursday, December 13th.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Liberty Wealth Management LLC bought a new position in Johnson & Johnson in the 4th quarter worth $126,000. Atwater Malick LLC bought a new position in Johnson & Johnson in the 4th quarter worth $3,827,000. Pinnacle Bank bought a new position in Johnson & Johnson in the 4th quarter worth $2,390,000. Centric Wealth Management bought a new position in Johnson & Johnson in the 4th quarter worth $1,506,000. Finally, Jackson Hole Capital Partners LLC bought a new position in Johnson & Johnson in the 4th quarter worth $243,000. 67.28% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 22nd. The company reported $1.97 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.95 by $0.02. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The company had revenue of $20.39 billion during the quarter, compared to analysts’ expectations of $20.27 billion. During the same quarter in the prior year, the company earned $1.74 EPS. The firm’s revenue was up 1.0% on a year-over-year basis. As a group, equities research analysts expect that Johnson & Johnson will post 8.58 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, March 12th. Shareholders of record on Tuesday, February 26th were given a dividend of $0.90 per share. The ex-dividend date of this dividend was Monday, February 25th. This represents a $3.60 annualized dividend and a yield of 2.58%. Johnson & Johnson’s payout ratio is currently 44.01%.
Johnson & Johnson announced that its Board of Directors has authorized a stock buyback plan on Monday, December 17th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to buy up to 1.5% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Why does a company issue an IPO?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.